Biography
- Medical Director, Hematological Malignancy Program (Leukemia/Lymphoma), Ann & Robert H. Lurie Children’s Hospital of Chicago
- Attending Physician, Hematology, Oncology, Neuro-Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children’s Hospital of Chicago
- Associate Professor of Pediatrics (Hematology, Oncology, and Stem Cell Transplantation), Northwestern University Feinberg School of Medicine
See Lurie Children's Provider Profile
Sara Zarnegar-Lumley, MD, specializes in pediatric hematologic malignancies such as leukemia, lymphoma, and histiocytosis. She has a particular interest in myeloid diseases such as acute myeloid leukemia and germline conditions that predispose patients to myeloid malignancy. Dr. Zarnegar-Lumley is a clinical investigator who is actively involved in the Children’s Oncology Group and serves as a study chair for a targeted therapy of a molecularly defined subset of pediatric AML. She participates in the Children’s Oncology Group Myeloid Disease committee and serves on the Infant ALL Task Force and study committee for a clinical trial for relapsed/refractory KMT2A-rearranged infant leukemia.
Dr. Zarnegar-Lumley is also invested in patient-centered research and practice. She serves as the Young Investigator Liaison for the Children’s Oncology Group Return of Results Committee, a group that is dedicated to providing lay summary results of completed Children’s Oncology Group research studies to study participants. She has conducted research related to oncofertility counseling and is a member of the Lurie Children’s Fertility Preservation and Hormone Restoration Program.
Education and Background
- Fellowship in pediatric hematology oncology, Memorial Sloan Kettering Cancer Center and New York Presbyterian Hospital/Weill Cornell Medical College 2014–2017
- Residency in pediatrics, Northwestern University McGaw Medical Center 2011–2014
- MD, Georgetown University School of Medicine 2011
Research Highlights
REAL-WORLD CLINICAL USE OF IDH INHIBITORS IN PEDIATRIC PATIENTS WITH MYELOID MALIGNANCIES
The purpose of this research is to gather multi-institutional data about the clinical use of IDH inhibitors in patients treated at pediatric oncology centers with myeloid malignancies, including AML or MDS. Collective data on the tolerability and potential efficacy of IDH inhibitors in pediatric patients with this rare genetic subset of AML may better inform future clinical trial development.
SELCLAX: A PHASE 1 AND EXPANSION COHORT STUDY OF VENETOCLAX AND SELINEXOR IN COMBINATION WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH REFRACTORY OR RELAPSED AML OR ALAL
This multi-institutional study, for which Dr. Zarnegar-Lumley is the co-PI and was involved in protocol design and implementation, is evaluating a novel therapeutic approach in difficult to treat pediatric AML. This approach seeks to abrogate resistance to apoptosis modulation and enhance leukemia cell death.
